In yet another pharmaco agreement, Glenmark Pharma entered into an agreement with Triax and Astellas in order to resolve a patent infringement case in the US. The chemical in question was the generic hydrocostisone butyrate cream, used to treat skin infections.
Hydrocortisone butyrate cream is a generic version of Triax's Locoid Lipocream.
Under the settlement and licence pact, "Glenmark will be permitted to market and distribute its 0.1 per cent hydrocortisone butyrate cream under a royalty-bearing license from Astellas and Triax in the US near the end of 2013."
